ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
UBS Global Healthcare Conference 9:00 am ET, May 25, 2016
Jefferies 2016 Healthcare Conference
10:00 am ET, June 9, 2016
The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, has demonstrated encouraging activity and tolerability in early clinical testing for folate receptor α-positive ovarian cancer and is progressing to advanced clinical testing. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20160511005165/en/
News Provided by Acquire Media